Shares of Biogen Inc. BIIB shed 1.44% to $115.29 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 2.24% to 5,275.70 and Dow ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's ...

Biogen Inc. and Genentech Inc. are heading to trial in June over a significant contract dispute concerning patent royalties ...

The European Commission (EC) has at last granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Biogen (BIIB – Research Report), with a price target ...

Jefferies analyst Michael Yee maintained a Hold rating on Biogen (BIIB – Research Report) today and set a price target of $130.00. The ...

Shares of Biogen Inc. BIIB slipped 5.90% to $113.38 Thursday, on what proved to be an all-around rough trading session for ...

Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.